105 related articles for article (PubMed ID: 10803317)
1. Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging.
Manyak MJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):127-30. PubMed ID: 10803317
[No Abstract] [Full Text] [Related]
2. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
[TBL] [Abstract][Full Text] [Related]
4. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Manyak MJ; Hinkle GH; Olsen JO; Chiaccherini RP; Partin AW; Piantadosi S; Burgers JK; Texter JH; Neal CE; Libertino JA; Wright GL; Maguire RT
Urology; 1999 Dec; 54(6):1058-63. PubMed ID: 10604708
[TBL] [Abstract][Full Text] [Related]
5. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney.
Valliappan S; Joyce JM; Myers DT
Clin Nucl Med; 1999 Dec; 24(12):984-5. PubMed ID: 10595486
[No Abstract] [Full Text] [Related]
6. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
8. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
[TBL] [Abstract][Full Text] [Related]
10. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
[TBL] [Abstract][Full Text] [Related]
11. The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer.
Freeman LM; Krynyckyi BR; Li Y; Korupulu G; Saleemi K; Haseman MK; Kahn D;
Q J Nucl Med; 2002 Jun; 46(2):131-7. PubMed ID: 12114876
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
Shore ND
Urology; 2010 Nov; 76(5):1167-8; author reply 1168. PubMed ID: 21056261
[No Abstract] [Full Text] [Related]
13. Indium-111 capromab pendetide (ProstaScint) images before and after salvage radiation therapy.
Welsh JS; Yanez MH; Chin BB; Howard SP
Clin Nucl Med; 1999 Dec; 24(12):983. PubMed ID: 10595485
[No Abstract] [Full Text] [Related]
14. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Olsen JO; Williams BS; Lamatrice RA; Barth RF; Rogers B; Maguire RT
J Nucl Med; 1998 Apr; 39(4):650-2. PubMed ID: 9544673
[TBL] [Abstract][Full Text] [Related]
15. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation.
Haseman MK; Reed NL; Rosenthal SA
Clin Nucl Med; 1996 Sep; 21(9):704-13. PubMed ID: 8879871
[TBL] [Abstract][Full Text] [Related]
17. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
[TBL] [Abstract][Full Text] [Related]
18. Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland.
Mouraviev V; Madden JF; Broadwater G; Mayes JM; Burchette JL; Schneider F; Smith J; Tsivian M; Wong T; Polascik TJ
J Urol; 2009 Sep; 182(3):938-47. PubMed ID: 19616259
[TBL] [Abstract][Full Text] [Related]
19. Indium-111 capromab pendetide in the management of recurrent prostate cancer.
Manyak MJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):175-81. PubMed ID: 18279057
[TBL] [Abstract][Full Text] [Related]
20. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
